HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Review Of Colgate Optic White Claims Delays Class Action Complaint

This article was originally published in The Pink Sheet

Executive Summary

A Colgate Optic White whitening claims class action complaint is stayed pending an FTC decision on the claims, a federal judge rules. The judge denied the Colgate's motion to dismiss on the grounds the state suit is pre-empted by FDA regulations.

You may also be interested in...



Oral Care, Topical Product 'Natural' Claims Paint Bullseye For Class Action

Class action complaints alleging misleading "natural" claims for food products have been stayed pending completion of FDA's look at whether it should formally define the term for use in food, but there is no parallel FDA consideration of how the term is used for oral care products and topicals.

Supreme Court Rejects Most Pharma Cases This Term, But Patent Settlements Stir Interest

High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.

J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation

Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel